What is Avalo Therapeutics's D&A?

Avalo Therapeutics (AVTX) reported D&A of $17K in Q1 2026.

How has Avalo Therapeutics's D&A changed year-over-year?

Avalo Therapeutics's D&A decreased by 87.4% year-over-year, from $135K to $17K.

What is the long-term trend for Avalo Therapeutics's D&A?

Over 4 years (2021 to 2025), Avalo Therapeutics's D&A has grown at a -31.6% compound annual growth rate (CAGR), from $1.58M to $344K.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Avalo Therapeutics AVTX D&A

D&A at other companies

XencorXNCR

$2.57M-4.7%

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

Absci CorporationABSI

$2.73M-11.2%

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's D&A?: Avalo Therapeutics (AVTX) reported D&A of $17K in Q1 2026.
How has Avalo Therapeutics's D&A changed year-over-year?: Avalo Therapeutics's D&A decreased by 87.4% year-over-year, from $135K to $17K.
What is the long-term trend for Avalo Therapeutics's D&A?: Over 4 years (2021 to 2025), Avalo Therapeutics's D&A has grown at a -31.6% compound annual growth rate (CAGR), from $1.58M to $344K.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.